



## **ANNOUNCEMENT NO. 213**

27 October 2021

### **Revenue and EBITDA guidance raised**

ChemoMetec has continued its positive development into the first quarter of the financial year 2021/22, where sales and order intake developed better than expected especially in the North American region.

ChemoMetec now expects revenue in the financial year 2021/22 in the DKK 335-345 million range, up from DKK 316-326 million, and EBITDA in the DKK 160-165 million range, up from DKK 150-155 million.

ChemoMetec expects to release its Q1 2021/22 trading statement (1 July to 30 September 2021) on Thursday, 4 November 2021.

#### **For further information**

Steen Søndergaard, CEO, ChemoMetec A/S,

Telefon: (+45) 4813 1020

#### **About ChemoMetec A/S**

*ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec's instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec's customers include some of the world's leading pharmaceutical companies such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.*

*ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For more information, go to [www.chemometec.com](http://www.chemometec.com).*